心脏术后血浆成纤维细胞生长因子23升高与院内急性肾损伤相关
这项前瞻性观察研究纳入173例体外循环下非急诊冠脉搭桥和/或瓣膜手术患者,发现体外循环结束后6小时测得的cFGF23和iFGF23与术后院内全分期急性肾损伤相关,cFGF23每增加两倍对应OR为1.57(95%CI 1.26–1.96),校正后仍显著,但生物标志物的风险分层效用尚待确定。
要点
- 体外循环结束后6小时cFGF23翻倍与术后全分期AKI风险升高独立相关(校正后OR 1.40)。
- iFGF23翻倍同样与术后AKI风险升高相关(OR 1.59,95%CI 1.08–2.35)。
- 术后7天内AKI总发生率为18.5%,联合冠脉搭桥加瓣膜手术者达41.2%。
核心结论
- 体外循环心脏手术后早期测得的cFGF23和iFGF23与术后全分期院内急性肾损伤相关。
- 这些生物标志物用于心脏手术患者风险分层的效用仍待确定。
研究设计与样本
- 前瞻性观察研究,纳入173例体外循环下非急诊冠脉搭桥和/或瓣膜手术患者。
- 主要结局为术后第7天(或更早出院时)依据KDIGO血清肌酐标准定义的全分期院内急性肾损伤。
- 体外循环结束后6小时测量血浆iFGF23和cFGF23。
主要发现
- 术后第7天共32例发生院内急性肾损伤(18.5%)。
- 冠脉搭桥患者AKI发生率为18.5%,瓣膜手术为14.3%,联合冠脉搭桥加瓣膜手术为41.2%。
- cFGF23每增加两倍与术后AKI预测比值比1.57相关(95%CI 1.26–1.96,P<0.0001)。
- 校正临床协变量后cFGF23关联仍显著(OR 1.40,95%CI 1.10–1.77,P=0.006),校正术前Cleveland Clinic评分后亦显著(OR 1.54,95%CI 1.22–1.95,P=0.0003)。
- iFGF23每增加两倍与术后AKI预测比值比1.59相关(95%CI 1.08–2.35,P=0.018)。
临床怎么用
- 体外循环心脏手术后6小时可考虑检测cFGF23和iFGF23以辅助识别术后AKI高风险患者。
- 目前生物标志物的风险分层效用尚未确定,不能仅凭其改变临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute kidney injury (AKI) occurs in 20 to 30% of cardiac surgery patients and is most often classified as mild. A previous study reported that intact fibroblast growth factor 23 (iFGF23) and C-terminal fibroblast growth factor 23 (cFGF23) measured after cardiopulmonary bypass (CPB) were associated with severe AKI after cardiac surgery but did not analyze the association between iFGF23 and all-stage AKI. The primary aim of the study was to determine whether FGF23 biomarker measurements 6 h after CPB were associated with all-stage AKI after cardiac surgery. METHODS: This prospective observational study included 173 patients undergoing nonemergent coronary artery bypass graft (CABG) and/or valve surgery on CPB. The primary study outcome was all-stage postoperative in-hospital AKI defined using the Kidney Disease: Improving Global Outcomes serum creatinine criteria through postoperative day 7, or earlier if the hospital stay was less than 7 days. Plasma iFGF23 and cFGF23 were measured 6 h after the end of CPB. RESULTS: A total of 32 patients developed in-hospital postoperative AKI (18.5%) by the seventh postoperative day. The incidence of AKI was 18.5% in CABG patients, 14.3% in valve surgery patients, and 41.2% in combined CABG valve patients. A two-fold increase in cFGF23 was associated with 1.57 greater predicted odds of developing in-hospital postoperative AKI (odds ratio [OR], 1.57; 95% CI, 1.26 to 1.96; P < 0.0001). This association remained significant after adjusting for clinical covariates (OR, 1.40; 95% CI, 1.10 to 1.77; P = 0.006) and after adjusting for preoperative Cleveland Clinic score (OR, 1.54; 95% CI, 1.22 to 1.95; P = 0.0003). A two-fold increase in iFGF23 was associated with 1.59 greater predicted odds of developing in-hospital postoperative AKI (OR, 1.59; 95% CI, 1.08 to 2.35; P = 0.018). CONCLUSIONS: Early postoperative measurements of cFGF23 and iFGF23 are associated with all-stage AKI after cardiac surgery. The utility of these biomarkers for risk classification in cardiac surgery patients remains to be determined.
引用
- Cheruku SR, Neyra JA, Mohammad H, et al. Increased Plasma Fibroblast Growth Factor 23 and In-hospital Acute Kidney Injury after Cardiac Surgery. Anesthesiology. 2025. PMID: 40489631. doi:10.1097/ALN.0000000000005605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。